OPRK1 and major depressive disorder: Perhaps the most compelling clinical data supporting antidepressant effects of KOR antagonists come from a recent study in which a combination of buprenorphine and the potent MOR antagonist samidorphan administered to subjects with treatment resistant MDD resulted in significant and substantial antidepressant activity without addictive potential (Ehrich et al., 2015).